Lithium and Strattera (Atomoxetine) Combination
While the FDA label for Strattera does not specifically list lithium as a contraindicated or interacting medication, caution is warranted when combining these agents, particularly given lithium's known cardiac effects and the need for careful monitoring of both medications. 1
Key Safety Considerations
No Direct Pharmacokinetic Interaction
The Strattera FDA label does not identify lithium among its contraindicated medications or major drug interactions. The primary contraindications for Strattera include:
- MAOIs (absolute contraindication)
- Pheochromocytoma
- Severe cardiovascular disorders
- Narrow angle glaucoma 1
Cardiac Monitoring Concerns
Both medications can affect cardiac function, which requires heightened vigilance:
- Lithium can cause bradycardia, T-wave changes, AV-block, and has divergent reports regarding QT prolongation 2
- Strattera can increase blood pressure and heart rate by 15-20 mmHg and 20 beats per minute, respectively 1
The European Heart Journal guideline specifically notes that "caution should be taken in patients treated concomitantly with anti-arrhythmic drugs" when using lithium 2
Mood Destabilization Risk
Recent evidence suggests atomoxetine may contribute to mood destabilization in vulnerable individuals. A 2026 case report documented manic symptoms emerging in a patient with ADHD on atomoxetine, with mood stabilization achieved after initiating lithium 3. This suggests the combination may actually be therapeutic in some contexts, but highlights the need to monitor for mood changes.
Clinical Management Algorithm
When prescribing this combination:
Baseline Assessment:
- Obtain ECG to evaluate for pre-existing conduction abnormalities or QT prolongation
- Document baseline blood pressure and heart rate
- Ensure lithium levels are therapeutic and stable
Monitoring Schedule:
- Check blood pressure and heart rate at each dose adjustment
- Monitor lithium levels regularly (as standard lithium monitoring requires)
- Consider repeat ECG if patient develops cardiac symptoms or if lithium dose changes
Watch for Warning Signs:
- New or worsening bradycardia
- Symptoms of AV block (dizziness, syncope, fatigue)
- Excessive blood pressure elevation
- Mood destabilization or manic symptoms 3
Common Pitfalls to Avoid
- Don't assume no interaction means no monitoring needed - the absence of a listed interaction doesn't eliminate the need for vigilance with two medications affecting cardiovascular function
- Don't overlook mood changes - while atomoxetine is used for ADHD, it may trigger mood episodes in bipolar patients, even those on lithium 3
- Don't forget standard lithium monitoring - the addition of atomoxetine doesn't change the need for routine lithium level checks, renal function monitoring, and thyroid function tests
The combination is not contraindicated and can be used safely with appropriate cardiac and mood monitoring.